Johnson & Johnson (NYSE:JNJ) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it -0.88% to close at $113.13 with the total traded volume of 9.03 Million shares. Swiss bio-pharmaceutical firm, Actelion Ltd. gained about 17% on Friday following drug major Johnson & Johnson (JNJ) confirmed its preliminary talks with Actelion regarding a potential transaction. In its statement, Johnson & Johnson stated there can be no assurance any transaction will result from these discussions.
The firm does not intend to make any additional comments regarding these talks unless and until it is appropriate to do so, or a formal contract has been reached, it stated. In Zurich, Actelion shares climbed 16.8 percent to 184.50 Swiss francs, valuing it at almost 19.9 billion francs. Earlier, Bloomberg reported, citing people familiar with the matter, that Johnson & Johnson has approached Actelion for a potential takeover, and that Actelion is working with an adviser to explore options. The firm has institutional ownership of 65.80%, while insider ownership included 0.02%. Its price to sales ratio ended at 4.30. JNJ attains analyst recommendation of 2.40 with week performance of -1.93%.
Northrop Grumman Corporation (NYSE:NOC) [Trend Analysis] surged reacts as active mover, shares an raise 0.15% to traded at $248.96 and the percentage gap among open changing to regular change was -0.69%. Northrop Grumman Corporation (NOC) revealed that it has priced a $750 million underwritten public offering of 3.20% senior unsecured notes due Feb. 1, 2027. Northrop Grumman expects to use the net proceeds from the offering for general corporate purposes, comprising debt repayment, pension plan funding and working capital.
Northrop Grumman Corporation also reported that its wholly owned subsidiary, Northrop Grumman Systems Corporation, will redeem for cash all of its outstanding 6.75% Senior Notes due April 2018 on Dec. 28, 2016. The Notes will be redeemed at a “make-whole” premium price, calculated in accordance with the Notes and the indenture and supplemental indentures governing the Notes.
Northrop Grumman presently expects the Make-Whole Redemption to result in a pre-tax charge of about $15 million in the fourth quarter of 2016, which is contemplated in the firm’s 2016 financial guidance. As of the date of this press release, $200 million aggregate principal amount of the Notes were outstanding. The firm’s current ratio calculated as 1.10 for the most recent quarter. The firm past twelve months price to sales ratio was 1.84 and price to cash ratio remained 39.78. As far as the returns are concern, the return on equity was recorded as 37.80% and return on investment was 19.10% while its return on asset stayed at 8.80%. The firm has total debt to equity ratio measured as 0.00.